Viewing Study NCT00001859


Ignite Creation Date: 2025-12-24 @ 2:59 PM
Ignite Modification Date: 2026-01-01 @ 11:24 AM
Study NCT ID: NCT00001859
Status: COMPLETED
Last Update Posted: 2019-12-17
First Post: 1999-11-03
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Screening for Patients Needing Kidney, Kidney-Pancreas, or Islet-Cell Transplant
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Organization:

Study Overview

Official Title: Screening Protocol for Patients Needing a Kidney, Kidney-Pancreas, or Islet Cell Transplant
Status: COMPLETED
Status Verified Date: 2014-05-30
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Kidney transplantation is the preferred treatment for most end-stage kidney disease. This procedure is limited, however, by two major factors: 1) a shortage of donor organs and 2) organ rejection by the recipient. The National Institute of Diabetes and Digestive and Kidney Diseases is screening patients with kidney failure or diabetes who may be eligible for kidney, kidney and pancreas, or islet cell transplantation.

Patients in this screening study are not offered treatment. When the screening is complete, patients will be offered an opportunity to participate in another institute study, or, if there are no active studies appropriate for the patient, other options will be suggested to the primary or referring physician. Patients found eligible for a study are not obligated to participate.

Screening for all patients typically consists of blood tests, urinalysis, electrocardiogram, PPD tuberculosis screen and pregnancy test. Chest and kidney X-rays and other studies may be done on patients determined eligible for a particular study, including transplantation. A summary of all test results will be sent to the referring physician unless the patient requests otherwise.

...
Detailed Description: This protocol is designed for screening of patients with renal failure and/or diabetes who may be eligible for kidney, kidney-pancreas, or islet cell transplantation. Its purpose is to allow detailed investigation into the renal and endocrine function of these patients, and the status of other organ systems that would determine their ability to safely tolerate specific aspects of other therapeutic research protocols. After completion of this screening process, the patient will either be offered a chance to participate in an active treatment protocol, or if no appropriate protocol is identified, will have recommendations for other treatment options relayed to the primary or referring physicians.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
99-DK-0120 None None View